NEW YORK (TheStreet) -- Express Scripts (ESRX) shares are down 1.8% to $85.56 in trading on Monday after the pharmacy benefit management organization's stock was downgraded to "market perform" from "outperform" by analysts' at Raymond James.
The firm also removed the company's $92 price target in response to Friday's revelation that the company was not in the running to purchase health insurance company Humana (HUM).
Humana shares rose 20% in trading on Friday following reports that it is exploring a possible sale using Goldman Sachs (GS) as fellow insurers Aetna (AET) and Cigna (CI) are among the parties interested in a deal.
Today Humana shares are up 0.2% to $21.5.17,while Aetena and Cigna shares are up 1.11% and 2.68%, respectively.
Separately, Humana's CEO sent an internal email to employees today acknowledging the distracting nature of the press reports about the company and encouraging employees to continue to do their jobs.
TheStreet Ratings team rates EXPRESS SCRIPTS HOLDING CO as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate EXPRESS SCRIPTS HOLDING CO (ESRX) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins."